Business
Sernova Signs Collaboration Agreement to Advance Conformal Coated Immune Protected Therapeutic Cells for Diabetes with the University of Miami
(TheNewswire) Collaboration to build on positive Cell Pouch T1D Clinical Outc...
About this update from Sernova Biotherapeutics Inc
[{"type":"text","content":"Sernova Signs Collaboration Agreement to Advance Conformal Coated Immune Protected Therapeutic Cells for Diabetes with the University of Miami\n \n \n (TheNewswire)\n \n \n \n \n \n \n \n \n Collaboration to\nbuild on positive Cell Pouch T1D Clinical Outcomes and preclinical\nsuccess in Global Pharmaceutical Collaborations to develop\nregenerative medicine therapeutic cures without life-long\nimmunosuppression medications across multiple diseases\n \n \n \n \n An information\nsession featuring Dr. Alice Tomei,\n \n \n a leading international\nexpert in immunoprotection and diabetes immunoengineering\n \n \n at the University of\nMiami, will take place on September 20th, 2021, at 1:00 PM EDT\n \n \n \n \n LONDON, ONTARIO -\n \n \n TheNewswire -\n \n \n September 16, 2021 - Sernova Corp. (TSXV:SVA)\n(OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicine\ncompany developing a ‘functional cure’ for type 1 diabetes (T1D)\nand other chronic diseases, announced today it has entered into a\nresearch agreement with the University of Miami to advance the\ndevelopment of our Cell Pouch™ cell therapy platform combined with\nthe novel conformal coating cellular immune protection technology.\n \n \n \n \n Dr. Alice Tomei, of the renowned Diabetes Research\nInstitute (DRI) at the University of Miami Miller School of Medicine,\nis an associate professor and international expert in immunoprotection\nand diabetes immunoengineering. As part of this important\ncollaboration, Dr. Tomei and her team is working closely with\nSernova’s R&D team. The expert teams have developed a series of\nkey preclinical and polymer characterization studies. In addition,\nwork is being conducted to scale-up the conformal coating technology\nprocess. The ultimate goal of this work is to support and accelerate\nthe anticipated clinical evaluation of the Cell Pouch platform without\nthe need for immunosuppression in patients with brittle T1D.\n \n \n \n \n While the studies will focus on immune protection of\ninsulin producing cells in the Cell Pouch, these technology advances\nare expected to be directly relevant and applicable to an array of\ncell technologies for treatment of multiple cell therapy\napplications.\n \n \n \n \n Dr. Tomei stated, “We have developed and optimized\nthe conformal coating technologies over ...